Rapid diagnostics first, then revolutionary antibiotics will follow
This article was originally published in Clinica
Executive Summary
Rapid diagnostics that can be used to identify the right study patients, enrich clinical trials, improve clinical care and stewardship, and help get drugs approved for limited populations will be an essential factor to reinvigorating the antibiotic pipeline and quelling the tide of multi-drug resistant infections, stakeholders echoed over and over again at a recent workshop organized by the National Institutes of Health and the US FDA.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.